Atena Mansouri

Dr. Atena Mansouri


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AMAtena Mansouri
Atena Mansouri
KAKhalil Abnous
Khalil Abnous
MAMona Alibolandi
Mona Alibolandi
STSeyed Mohammad Taghdisi
Seyed Mohammad Taghdisi
MRMohammad Ramezani
Mohammad Ramezani

8 March 2024 in Gene
Verified
Journal Article
Closed access
RVRamin Vosooghi
Ramin Vosooghi
AMAlireza Motavalizadehkakhky
Alireza Motavalizadehkakhky
AMAtena Mansouri
Atena Mansouri
JMJamshid Mehrzad
Jamshid Mehrzad
MHMasood Homayouni
Masood Homayouni

20 December 2024 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
MFMohammad Fereidouni
Mohammad Fereidouni
MSMehri Shadi
Mehri Shadi
RMReihaneh Alsadat Mahmoudian
Reihaneh Alsadat Mahmoudian
JGJavad Ghasemi
Javad Ghasemi
MMMohammad Erfan Mahzoon
Mohammad Erfan Mahzoon
AMAtena Mansouri
Atena Mansouri

29 July 2023 in Archives of Medical Science
Verified
Journal Article
Closed access
SGShiva Ganjali
Shiva Ganjali
AMAtena Mansouri
Atena Mansouri
ŽRŽeljko Reiner
Željko Reiner
TJTannaz Jamialahmadi
Tannaz Jamialahmadi
SMSeyed Adel Moallem
Seyed Adel Moallem
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Introduction: This study aimed to evaluate the TRE-induced changes in the serum expression levels of miRNAs associated with lipids metabolism and autophagy process in MI patients to assess the potential protective effects of TRE in these patients.Material and methods: This post hoc investigation was performed on serum samples obtained from a pilot randomized, double blind, placebo-controlled clinical trial that recruited 14 men (aged 18-80) who had MI and systemic inflammation. The patients were randomized in a 2:1 ratio to either TRE (15 g/week, intravenous (IV) ad-ministration) (N=10) or placebo groups (equal volume of saline 0.9 %) (N=4) for a period of 12 weeks. To measure the relative serum expression levels of miRNA-155, miRNA-221, and miRNA-33, the SYBR Green qPCR method was used.Results: miRNA-155 showed significantly higher serum expression levels in the TRE group (2.772±0.73; P=0.009) when compared to the placebo group. Also, significant reductions in miRNA-155 (0.171±0.03; P=0.016), miRNA-221 (0.116±0.07; P=0.013), and miRNA-33a (0.076±0.07; P=0.025) were observed in the placebo group at the end of the study. Nevertheless, the reduction (normalized to the baseline) of the serum expres-sion levels of miRNA-221 (FC:0.87±0.20 vs FC:0.18±0.08; P=0.009) and miRNA-33a (FC:0.73±0.22 vs FC:0.13±0.08; P=0.025) were significantly less in TRE group than in the placebo group.Conclusions: IV TRE administration did not reduce the expression of miRNA-221 and miRNA33a as much as placebo. Keeping a steady state of the serum expression levels of these miRNAs associated with lipoproteins metabolism and autophagy in the TRE group might have protective effects in patients with MI.

29 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
EZElahe Zeinali
Elahe Zeinali
VBVahid Bagheri
Vahid Bagheri
EREsmaeil Rostami
Esmaeil Rostami
AMAtena Mansouri
Atena Mansouri
GSGholamreza Anani Sarab
Gholamreza Anani Sarab
Background Resistant cells are a critical problem that reduce treatment efficacy of breast cancer. Nowadays, CIP2A and PD-L1 are considered as theraputical challenges in breast cancer, because of responsible for drug resistance and immune evasion respectively. Hence, identifying agents to suppress these factors is great of interest. Specifically, epigenetic drugs can be an effective approach to alter the behavior of genes. Objective The objective of this study is to evaluate the drug effects and molecular mechanisms of valproic acid (VPA) as a HDAC inhibitor, particularly its effect on CIP2A and PD-L1 in breast cancer MCF-7 cell line. Materials and Methods In this study, MCF-7 cells were treated with various concentration of VPA for 24 h, 48 h, and 72 h. The rate of cell viability was measured by MTT assay. Finally, gene expressions of CIP2A, c-MYC, PI3K, Akt, mTOR and PD-L1 were analyzed by real time PCR and ΔCT method. Result VPA showed a growth inhibitory effect in MCF-7 cell line. This effect is achieved by decreasing the expression levels of CIP2A oncogene and its downstream signaling molecules i.e. c-MYC, PI3K, Akt and mTOR. In addition to being a CIP2A targeting agent, VPA also inhibits PD-L1 in MCF-7 cell line. Conclusions Our findings suggest that VPA can be a novel approach to combat with challenges caused by CIP2A and PD-L1, thereby alone or in combination with existing therapies could be promising strategy to get more efficiencies in treatments for breast cancer patients.